Exclusive-Illumina, Grail deal faces full-scale EU antitrust probe -sources By Reuters
By Foo Yun Chee BRUSSELS (Reuters) - U.S. life sciences company Illumina Inc (NASDAQ:ILMN)'s proposed buy of cancer test maker Grail Inc faces a lengthy EU antitrust investigation if it does not offer hefty concessions this week, people familiar with the matter said on Tuesday. Illumina announced the $8 billion cash-and-stock deal for cancer screening startup Grail Inc last September under which it will buy out investors, including Amazon.com Inc (NASDAQ:AMZN) founder Jeff Bezos, to regain control of a company it spun out five years ago. Last month, the European Commission opened a preliminary review into...
Continue reading